AbbVie (ABBV) Long-Term Debt Issuances (2015 - 2026)
AbbVie (ABBV) reported Long-Term Debt Issuances of $8.0 billion for Q1 2026, up 100.08% year-over-year from $4.0 billion in Q1 2025, and up 100.08% on a QoQ basis from $4.0 billion in Q1 2025.
AbbVie (ABBV) has 8 years of Long-Term Debt Issuances data on file, last reported at $8.0 billion in Q1 2026.
- Quarterly Long-Term Debt Issuances rose 100.08% year-over-year to $8.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.0 billion (up 33.32% YoY) and the FY2025 annual result came in at $4.0 billion, down 76.45% from the prior year.
- Long-Term Debt Issuances rose to $8.0 billion in Q1 2026 per ABBV's latest filing, from $4.0 billion in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $15.0 billion in Q1 2024 and bottomed at $2.0 billion in Q1 2022.
- The 4-year median for Long-Term Debt Issuances is $4.0 billion (2025), against an average of $6.2 billion.
- The widest annual swing landed in 2025, when Long-Term Debt Issuances tumbled 73.31%; it then jumped 100.08% in 2026.
- Tracing ABBV's Long-Term Debt Issuances over 4 years: stood at $2.0 billion in 2022, then changed by 0.0% to $2.0 billion in 2024, then jumped by 99.7% to $4.0 billion in 2025, then jumped by 100.08% to $8.0 billion in 2026.
- Per Business Quant, the three latest ABBV Long-Term Debt Issuances figures stand at $8.0 billion (Q1 2026), $4.0 billion (Q1 2025), and $2.0 billion (Q4 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | - |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 7.99 Bn |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | - |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 3.96 Bn |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | - |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 7.99 Bn |
| Mar 31, 2026 | 7.99 Bn |
| Mar 31, 2025 | 3.99 Bn |
| Mar 31, 2025 | 3.99 Bn |
| Dec 31, 2024 | 2.00 Bn |
| Dec 31, 2024 | 2.00 Bn |
| Mar 31, 2024 | 14.96 Bn |
| Mar 31, 2024 | 14.96 Bn |
| Mar 31, 2022 | 2.00 Bn |
| Mar 31, 2022 | 2.00 Bn |
| Sep 30, 2021 | 1.00 Bn |
| Sep 30, 2021 | 1.00 Bn |
| Dec 31, 2019 | 29.95 Bn |
| Dec 31, 2019 | 29.95 Bn |
| Dec 31, 2016 | 3.86 Bn |
| Dec 31, 2016 | 3.86 Bn |
| Dec 31, 2015 | 4.00 Bn |
| Dec 31, 2015 | 4.00 Bn |
| Sep 30, 2015 | 5.00 Mn |
| Sep 30, 2015 | 5.00 Mn |